IDEXX LABORATORIES INC /DE
Close on Oct 19, 2026
- Market cap
- $44.08B
- P/E (TTM)
- 39.1
- Dividend yield
- –
About Idexx Laboratories
In Vitro & In Vivo Diagnostic Substances, SIC 2835
IDEXX Laboratories, Inc. develops, manufactures, and distributes diagnostic products and services primarily for companion animal veterinary care, livestock, poultry, dairy, and water testing. Operating through its Companion Animal Group, Water quality products, Livestock, Poultry and Dairy, and human diagnostics segments, the company serves veterinarians, biomedical researchers, livestock producers, water utilities, and diagnostic laboratories. Its offerings include point-of-care analyzers, consumables, rapid assays, reference laboratory services, practice management software, diagnostic imaging, and microbiological water tests.
The company maintains a commercial presence across North America, Europe, Asia Pacific, Latin America, and Africa. It operates a network of approximately 80 reference laboratories serving clients across countries including the United States, Canada, Australia, Japan, New Zealand, South Africa, and South Korea. IDEXX operates manufacturing and distribution facilities in Westbrook and Scarborough, Maine; Roswell, Georgia; Memphis, Tennessee; as well as the Netherlands, Switzerland, France, and the United Kingdom.
Summary of the business section of Idexx Laboratories's latest annual report, written by StockData.
Company profile
Company
- Legal name
- IDEXX LABORATORIES INC /DE
- Founded
- 1983
- Headquarters
- Westbrook, ME
- Address
- One Idexx Drive 04092-2041
- Phone
- (207) 556-0300
- Website
- www.idexx.com
- Employees
- 11,000, Dec 31, 2025
- Industry
- In Vitro & In Vivo Diagnostic Substances
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- IDXX
- Exchange
- Nasdaq
- IPO date
- Jun 21, 1991
- Shares outstanding
- 79M, Jul 31, 2026
- Public float
- $42.90B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 2-for-1, Jun 30, 2015; 2-for-1, Jun 16, 2015; 2-for-1, Nov 27, 2007; 2-for-1, Jun 6, 1995; 2-for-1, Oct 4, 1993
- SEC CIK
- 874716
- CUSIP
- 45168D104
- ISIN
- US45168D1046
- LEI
- OGMTXK0LUU1HKV2P0J84
- EIN
- 01-0393723
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jonathan Jay Mazelsky | President and CEO, Director | 83,803 |
| Andrew Emerson | EVP, CFO and Treasurer | 4,507 |
| George Fennell | Executive Vice President | 10,717 |
| Sharon E. Underberg | EVP, GC & Corporate Secretary | 7,138 |
| Nimrata Hunt | Executive Vice President | 18,301 |
| Michael G. Erickson | Executive Vice President | 15,092 |
| Michael Schreck | Executive Vice President | 2,123 |
| Michael Perkins Johnson | Executive Vice President | 2,795 |
| Martin Alexander Smith | Executive Vice President | 1,603 |
| Michael Lane | Executive Vice President | 8,169 |
| Brian P. McKeon | EVP, CFO and Treasurer | 49,600 |
| Lawrence D. Kingsley | Director | 9,568 |
| Joseph L. Hooley | Director | 325 |
| Irene Chang Britt | Director | 208 |
| Bruce L. Claflin | Director | 1,721 |
| Sam Samad | Director | 0 |
| Stuart Essig | Director | 2,236 |
| Karen Peacock | Director | 102 |
| Sophie V. Vandebroek | Director | 9,078 |
| Daniel M. Junius | Director | 3,561 |
| M. Anne Szostak | Director | 2,320 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Jonathan J. Mazelsky | $14.58M | $31.76M | $3.06M | $135 | $148 |
| FY2024 Jonathan J. Mazelsky | $13.01M | $2.33M | $3.77M | $83 | $129 |
| FY2023 Jonathan J. Mazelsky | $11.52M | $22.68M | $3.31M | $111 | $126 |
| FY2022 Jonathan J. Mazelsky | $9.79M | -$13.75M | $2.78M | $82 | $124 |
| FY2021 Jonathan J. Mazelsky | $9.07M | $28.21M | $2.85M | $132 | $126 |
| FY2020 Jonathan J. Mazelsky | $7.04M | $34.87M | $2.31M | $191 | $113 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had approximately 11,000 regular full-time and part-time employees in approximately 34 countries around the world, and men and women represented 41% and 59%, respectively, of our global employee population.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 6, 2007 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |